Abstract
Background. Sporadic primary hyperparathyroidism (pHPT) occurs separately and in several hereditary
disorders including multiple endocrine neoplasia type 1. Irradiation to the neck,
female gender, and age are well-identified risk factors that predispose to pHPT. The
multiple endocrine neoplasia type 1 gene is the most commonly deranged gene in parathyroid
adenomas and contains several polymorphisms including D418D with a prevalence of roughly
50%. Methods. We genotyped 162 pHPT patients and control participants to evaluate if the D418D
polymorphism is related to development of pHPT. One hundred fourteen of the pHPT patients
and control participants were recruited from a health screening and were subjected
to measurement of bone mineral density (BMD) at the lumbar spine, femoral neck, and
total body. Results. The prevalence of each genotype (ie, MM, Mm, and mm) was for all pHPT patients: 62%,
29%, and 9%; and for all control participants: 32%, 43%, and 25% (P <.0004). For the screening-detected pHPT patients and control participants, the genotype
distribution for MM, Mm, and mm was 60%, 30%, and 10%; and 31%, 44%, and 25%, respectively
(P =.009). In the screening-recruited control participants, but not in pHPT patients,
the MM genotype was also associated with higher total body BMD (P =.01) and BMD at the femoral neck (P =.02), whereas it failed to be significant for BMD at the lumbar spine (P =.08). Conclusions. We report that the MM genotype was overrepresented in pHPT patients compared with
control participants, suggesting a novel marker for pHPT. Furthermore, the MM genotype
was associated with higher BMD at the femoral neck and in the total body in the screening-recruited
control participants. (Surgery 2002;132:450-5.)
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Population-based health screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women.Surgery. 1997; 121: 287-294
- Clinical presentation of primary hyperparathyroidism.in: 1st ed. The parathyroids. : Raven Press, New York1994: 457-470
- Multiple endocrine neoplasia type 1.Endocr Relat Cancer. 1999; 6: 449-473
- Molecular pathology of parathyroid tumors.Trends Endocrinol Metab. 2001; 12: 53-58
- Hyperparathyroidism presenting as the first lesion in multiple endocrine neoplasia type 1 (MEN1).Am J Med. 1987; 82: 731-737
- Multiple endocrine neoplasia type 1 (MEN1).in: 1st ed. Endocrinology. : WB Saunders, Philadelphia1995: 2815-2831
- Positional cloning of the gene for multiple endocrine neoplasia type 1.Science. 1997; 276: 404-407
- Parathyroid MEN1 gene mutations in relation to clinical characteristics of non-familial primary hyperparathyroidism.J Clin Endocrinol Metab. 1998; 83: 2960-2963
- Alterations of the MEN1 gene in sporadic parathyroid tumors.J Clin Endocrinol Metab. 1998; 83: 2627-2630
- Somatic mutations of the MEN1 gene in parathyroid tumours.Nat Genet. 1997; 16: 375-378
- Somatic mutations of multiple endocrine neoplasia type 1 gene in the sporadic endocrine tumors.Lab Invest. 1998; 78: 471-475
- Screening of the MEN1 gene and discovery of germ-line and somatic mutations in apparently sporadic parathyroid tumors.Cancer Res. 2000; 60: 5553-5557
- Mutations of the multiple endocrine neoplasia type 1 gene in nonfamilial, malignant tumors of the endocrine pancreas.Cancer Res. 1998; 58: 377-379
- Mutations of the MEN1 tumor suppressor gene in pituitary tumors.Cancer Res. 1997; 57: 5446-5451
- Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription.Cell. 1999; 96: 143-152
- Menin represses JunD-activated transcription by a deacetylase-dependent mechanism.Biochim Biophys Acta. 1999; 1447: 51-56
- Cell cycle regulation of menin expression.Cancer Res. 1999; 59: 5097-5101
- Comparative genomic hybridization reveals frequent losses of chromosome 1p and 3q in pheochromocytomas and abdominal paragangliomas, suggesting a common genetic etiology.Am J Pathol. 2000; 156: 651-659
- Vitamin D receptor genotypes in primary hyperparathyroidism.Nat Med. 1995; 1: 1309-1311
- Vitamin D receptor alleles b, a and T: risk factors for sporadic primary hyperparathyroidism (HPT) but not HPT of uremia or MEN 1.Biochem Biophys Res Comm. 1997; 231: 329-332
- A prospective study of hyperparathyroidism in individuals exposed to radiation in childhood.JAMA. 1990; 264: 581-584
- Hyperparathyroidism in persons treated with x-rays for tuberculous adenitis.Cancer. 1997; 40: 846-854
- Monoclonality and abnormal parathyroid hormone genes in parathyroid adenomas.N Engl J Med. 1988; 318: 658-662
- Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma.N Engl J Med. 1994; 330: 757-761
- Allelic loss of the retinoblastoma tumor suppressor gene: a marker for aggressive parathyroid tumors?.J Clin Endocrinol Metab. 1996; 81: 3194-3196
- Absence of p53 point mutations in parathyroid adenoma and carcinoma.J Clin Endocrinol Metab. 1994; 78: 103-106
- Parathyroid tumor suppressor on 1p: analysis of the p18 cyclin-dependent kinase inhibitor gene as candidate.J Bone Miner Res. 1997; 12: 1330-1334
- Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study.J Clin Endocrinol Metab. 1996; 81: 1736-1739
- Expression of cyclin D1 in parathyroid carcinomas, adenomas and hyperplasias: a paraffin immunohistochemical study.Mod Pathol. 1999; 12: 412-416
- Vitamin D receptor (VDR) and parathyroid hormone messenger ribonucleic acid levels correspond to polymorphic VDR alleles in human parathyroid tumors.J Clin Endocrinol Metab. 1998; 83: 2255-2259
Article info
Footnotes
*Reprint requests: Pamela Correa, MD, Department of Surgical Sciences, Endocrine Unit, Uppsala University Hospital, SE-751 85 Uppsala, Sweden.
Identification
Copyright
© 2002 Mosby, Inc. Published by Elsevier Inc. All rights reserved.
